HomeREGULATORY
REGULATORY

Opdivo Clears MHLW Panel for 3rd Line Use in Gastric Cancer, Keytruda to Lose Sakigake Status
(Sep.8.2017)

A gastric cancer indication for Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) was reported to a key health ministry advisory panel on September 8, setting the stage for its official nod in around a month. The news bodes ill for its archrival Keytruda (pembrolizumab), however, as it now faces the revocation of its sakigake fast-track designation ...
(LOG IN FOR FULL STORY)

News Calendar